These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26833657)

  • 41. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
    Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
    Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review.
    Benden C; Haughton M; Leonard S; Huber LC
    J Heart Lung Transplant; 2017 Sep; 36(9):921-933. PubMed ID: 28662986
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction therapy in simultaneous pancreas-kidney transplantation: thymoglobulin versus basiliximab.
    Fernández-Burgos I; Montiel Casado MC; Pérez-Daga JA; Aranda-Narváez JM; Sánchez-Pérez B; León-Díaz FJ; Cabello-Díaz M; Rodríguez-Burgos D; Hernández-Marrero D; Santoyo-Santoyo J
    Transplant Proc; 2015; 47(1):120-2. PubMed ID: 25645787
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of basiliximab vs antithymocyte globulin for induction in pediatric heart transplant recipients: An analysis of the International Society for Heart and Lung Transplantation database.
    Butts RJ; Dipchand AI; Sutcliffe D; Bano M; Dimas V; Morrow R; Das B; Kirk R
    Pediatr Transplant; 2018 Jun; 22(4):e13190. PubMed ID: 29878688
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A contemporary analysis of induction immunosuppression in pediatric lung transplant recipients.
    Hayes D; Kirkby S; Wehr AM; Lehman AM; McConnell PI; Galantowicz M; Higgins RS; Whitson BA
    Transpl Int; 2014 Feb; 27(2):211-8. PubMed ID: 24236829
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation.
    Magliocca JF; Odorico JS; Pirsch JD; Becker YT; Knechtle SJ; Leverson GE; Sollinger HW
    Am J Transplant; 2008 Aug; 8(8):1702-10. PubMed ID: 18694474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis.
    Kulkarni HS; Cherikh WS; Chambers DC; Garcia VC; Hachem RR; Kreisel D; Puri V; Kozower BD; Byers DE; Witt CA; Alexander-Brett J; Aguilar PR; Tague LK; Furuya Y; Patterson GA; Trulock EP; Yusen RD
    J Heart Lung Transplant; 2019 Jan; 38(1):5-16. PubMed ID: 30391193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Basiliximab induction versus no induction in adult heart transplantation.
    Rudzik KN; Rivosecchi RM; Palmer BA; Hickey GW; Huston JH; Keebler ME; Kaczorowski DJ; Horn ET
    Clin Transplant; 2023 May; 37(5):e14937. PubMed ID: 36793206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience.
    Florescu DF; Seaman JA; Kalil AC; Qiu F; Bremers D; Westphal SG
    Transplant Proc; 2021 Apr; 53(3):1058-1063. PubMed ID: 32921434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of TGF-β in the Association Between Primary Graft Dysfunction and Bronchiolitis Obliterans Syndrome.
    DerHovanessian A; Weigt SS; Palchevskiy V; Shino MY; Sayah DM; Gregson AL; Noble PW; Palmer SM; Fishbein MC; Kubak BM; Ardehali A; Ross DJ; Saggar R; Lynch JP; Elashoff RM; Belperio JA
    Am J Transplant; 2016 Feb; 16(2):640-9. PubMed ID: 26461171
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS).
    Fisher AJ; Wardle J; Dark JH; Corris PA
    J Heart Lung Transplant; 2002 Nov; 21(11):1206-12. PubMed ID: 12431494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
    Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
    Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
    Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D
    Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients.
    Finlen Copeland CA; Snyder LD; Zaas DW; Turbyfill WJ; Davis WA; Palmer SM
    Am J Respir Crit Care Med; 2010 Sep; 182(6):784-9. PubMed ID: 20508211
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of aerosolized antipseudomonals on Pseudomonas positivity and bronchiolitis obliterans syndrome after lung transplantation.
    Moore CA; Pilewski JM; Venkataramanan R; Robinson KM; Morrell MR; Wisniewski SR; Zeevi A; McDyer JF; Ensor CR
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28273385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function.
    Knight RJ; Kerman RH; Schoenberg L; Podder H; Van Buren CT; Katz S; Kahan BD
    Transplantation; 2004 Sep; 78(6):904-10. PubMed ID: 15385812
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.
    Heng D; Sharples LD; McNeil K; Stewart S; Wreghitt T; Wallwork J
    J Heart Lung Transplant; 1998 Dec; 17(12):1255-63. PubMed ID: 9883768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.